Vadodara News Flash

Sickle Cell Disease Pipeline Drugs Analysis Report 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

 Breaking News
  • No posts were found

Sickle Cell Disease Pipeline Drugs Analysis Report 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

April 10
21:17 2023
Sickle Cell Disease Pipeline Drugs Analysis Report 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight
Sickle Cell Disease Pipeline
DelveInsight Evaluates a Robust Sickle Cell Disease Pipeline as 40+ Influential Pharma Players to Set Foot in the Domain

DelveInsight’s ‘Sickle Cell Disease Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Sickle Cell Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Sickle Cell Disease pipeline domain.

 

To know more about the Sickle Cell Disease pipeline report, click here @ Sickle Cell Disease Pipeline Analysis

 

Key Takeaways from the Sickle Cell Disease Pipeline Report

  • Over 50+ Sickle Cell Disease pipeline therapies are in various stages of development, and their anticipated acceptance in the Sickle Cell Disease market would significantly increase market revenue. 
  • Leading Sickle Cell Disease companies developing novel drug candidates to improve the Sickle Cell Disease treatment landscape include Bellicum Pharmaceuticals, Novartis, Novo Nordisk, Vertex Pharmaceuticals, and others.
  • Promising Sickle Cell Disease pipeline therapies in various stages of development include BPX-501 T cells, Canakinumab, EPI01, CTX001, and others.
  • In January 2020, Aruvant announced that the US Food and Drug Administration has granted Orphan Drug designation to ARU-1801, Aruvant’s investigational therapy for the treatment of sickle cell disease. The US Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to ARU-1801.
  • Mozobil (plerixafor) was initially developed by Genzyme. In April 2011, Sanofi acquired Genzyme and it turned into a wholly owned subsidiary.

 

Find out more about Sickle Cell Disease treatment drugs @ Drugs for Sickle Cell Disease Treatment

 

Sickle Cell Disease Overview

Sickle cell disease is the name given for a group of inherited conditions that affect the red blood cells and the most serious type is called Sickle cell anemia. Sickle cells are destroyed rapidly in the bodies of people with the disease, causing anemia which is why it is commonly known as sickle cell anemia.

The sickle cells also block the flow of blood through vessels, resulting in lung tissue damage that causes acute chest syndrome, pain episodes, stroke, priapism and damage to the spleen, kidneys and liver. Sickle cell disease is a serious and lifelong condition, although long-term treatment can help manage many of the problems associated with it. The disease affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body. There is an atypical hemoglobin molecule called hemoglobin S, which can distort red blood cells into a sickle, or crescent, shape. Sickle cell disease is caused by a mutation in the hemoglobin-Beta gene found on chromosome.

 

Sickle Cell Disease Drug Profile

BPX-501 T cells: Bellicum Pharmaceuticals

BPX-501 T cells (also known as Rivo-cel) is being developed by Bellicum Pharmaceuticals. BPX-501 T cells are derived from non-mobilized donor leukapheresis and are expanded, transduced and selected for the iC9 gene, cryopreserved and shipped back to the clinical site. Currently it is in Phase I/II stage of development for the treatment of Hematological Disorders. Rivo-cel is a T cell therapy incorporating CaspaCIDe safety switch intended to improve HSCT outcomes in the treatment of hematological malignancies and inherited blood disorders. Rivo-cel is designed to treat immunodeficiency following allogeneic HSCT, preventing morbidity and mortality due to disease relapse and infection. 

 

Discover more about the emerging Sickle Cell Disease drugs @ https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight

 

Sickle Cell Disease Companies:

Leading Sickle Cell Disease companies working in the treatment market are Cellectis, Sana Biotechnology, CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio,ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others.

 

Sickle Cell Disease Pipeline Therapies:

Some of the Sickle Cell Disease therapies developed by the major players in different phases include BPX-501 T cells, Canakinumab, EPI01, CTX001, and others.

 

Request for Sample Sickle Cell Disease Report @ Drugs for Sickle Cell Disease Treatment

 

Scope of the Sickle Cell Disease Pipeline Report 

  • Coverage: Global 
  • Key Sickle Cell Disease Companies: Cellectis, Sana Biotechnology, CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio,ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others
  • Key Sickle Cell Disease Pipeline Therapies: BPX-501 T cells, Canakinumab, EPI01, CTX001, and others
  • Sickle Cell Disease Pipeline Therapeutics Assessment (By development stage, By product type, By route of administration, By molecule type, )By MOA type

 

Find out more about the Sickle Cell Disease treatment options in development @ Sickle Cell Disease Clinical Trials

 

Table of Contents

1. Introduction

2. Executive Summary

3. Sickle Cell Disease Overview

4. Sickle Cell Disease Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Sickle Cell Disease Therapeutic Assessment

11. Inactive Sickle Cell Disease Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Sickle Cell Disease Unmet Needs

14. Sickle Cell Disease Market Drivers and Barriers

15. Appendix

16. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Related Articles